
==== Front
Nutr Diabetes
Nutr Diabetes
Nutrition & Diabetes
2044-4052
Nature Publishing Group UK London

39261487
332
10.1038/s41387-024-00332-z
Article
Associations of plasma phospholipid cis-vaccenic acid with insulin resistance markers in non-diabetic men with hyperlipidemia
Macášek Jaroslav 1
Staňková Barbora 12
Žák Aleš 1
Růžičková Markéta 1
Brůha Radan 1
Kutová Simona 1
http://orcid.org/0000-0002-3269-1817
Vecka Marek marek.vecka@lf1.cuni.cz

12
Zeman Miroslav 1
1 https://ror.org/04yg23125 grid.411798.2 0000 0000 9100 9940 Fourth Department of Internal Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, 128 08 Prague, Czech Republic
2 https://ror.org/04yg23125 grid.411798.2 0000 0000 9100 9940 Institute of Clinical Chemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Na Bojišti 3, 121 08 Prague, Czech Republic
11 9 2024
11 9 2024
2024
14 7323 1 2024
22 8 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

The role of fatty acids (FA) in the pathogenesis of insulin resistance and hyperlipidemia is a subject of intensive research. Several recent works have suggested cis-vaccenic acid (cVA) in plasma lipid compartments, especially in plasma phospholipids (PL) or erythrocyte membranes, could be associated with markers of insulin sensitivity and cardiovascular health. Nevertheless, not all the results of research work testify to these beneficial effects of cVA. Therefore, we decided to investigate the relations of proportion of cVA in plasma PL to markers of insulin resistance in hyperlipidemic men.

Subjects

In 231 men (median age 50) with newly diagnosed hyperlipidemia, we analyzed basic clinical parameters together with FA composition of plasma PL and stratified them according to the content of cVA into upper quartile (Q4) and lower quartile (Q1) groups. We examined also small control group of 50 healthy men.

Results

The individuals in Q4 differed from Q1 by lower plasma insulin (p < 0.05), HOMA-IR values (p < 0.01), and apolipoprotein B concentrations (p < 0.001), but by the higher total level of nonesterified FA (p < 0.01). Both groups had similar age, anthropometrical, and other lipid parameters. In plasma PL, the Q4 group had lower content of the sum of n-6 polyunsaturated FA, due to decrease of γ-linolenic and dihomo-γ-linolenic acids, whereas the content of monounsaturated FA (mainly oleic and palmitoleic) was in Q4 higher.

Conclusions

Our results support hypothesis that plasma PL cVA could be associated with insulin sensitivity in men with hyperlipidemia.

Subject terms

Fatty acids
Type 2 diabetes
https://doi.org/10.13039/501100001823 Ministerstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports) Charles University Research Program, Cooperatio-Gastroenterology Charles University Research Program, Cooperatio-Gastroenterology Charles University Research Program, Cooperatio-Gastroenterology Charles University Research Program, Cooperatio-Gastroenterology Staňková Barbora Žák Aleš Brůha Radan Vecka Marek https://doi.org/10.13039/501100003243 Ministerstvo Zdravotnictví Ceské Republiky (Ministry of Health of the Czech Republic) MH CZ DRO-VFN64165 MH CZ DRO-VFN64165 MH CZ DRO-VFN64165 NU23-01-00288 MH CZ DRO-VFN64165 Staňková Barbora Žák Aleš Brůha Radan Vecka Marek Zeman Miroslav issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Fatty acids (FA), as essential components of the lipid structure, play a number of important structural and functional roles in living organisms. They affect the properties of cell membranes and cell signaling, are ligands of nuclear factors, and are precursors of the plethora of biologically active molecules [1]. The composition of FAs in human body compartments depends on nutritional intake, endogenous synthesis, the functioning of enzymes desaturases and elongases (see Figs. 1 and 2), and different degradation mechanisms [2]. Moreover, racial and genetic factors play a role, as well [3, 4]. Dysregulation of FA is involved in the etiopathogenesis of insulin resistance. Inflammation and oxidative stress are important factors affecting insulin signaling, as well [5]. Insulin resistance (IR) was recognized to be associated with metabolic syndrome [6], type 2 diabetes mellitus (T2DM) development [7], and different pathological conditions, such as dyslipidemia, but also some cancers or neuropsychiatric diseases [8–10].Fig. 1 Metabolism of palmitic acid.

Palmitic acid can be converted into monounsaturated fatty acids of n-9 and n-7 families via activities of several long-chain fatty acid elongases (ELOVL 1,3,5–7) and desaturation with delta-9 desaturase (stearoyl-coenzyme A desaturase, SCD).

Fig. 2 Metabolism of polyunsaturated fatty acids.

Conversion of polyunsaturated fatty acids (PUFA) into members of PUFA n-3 and n-6 families includes two types of desaturases (FADS 1,2) and long chain fatty acid elongases (ELOVL 2,5). The distal part of the pathway also includes retroconversion by β-oxidation.

The relationships of individual classes of FA to insulin resistance, as well as to inflammation and oxidative stress, are different. Generally, a higher content of saturated fatty acids in the diet (especially palmitic acid) and a lower content of PUFA (polyunsaturated fatty acids) n-3, as well as monounsaturated FA (principally oleic acid) are mostly associated with insulin resistance [11], while the role of the n-6 PUFA class in this regard is less clear. In a recently published analysis of 20 studies, high plasma linoleic acid (LA, 18:2n-6) levels were associated with a significant decrease in the relative risk of T2DM [12], whereas the proportion of dihomo-γ-inolenic (20:3n-6) acid in serum cholesteryl esters positively correlated with the incidence of type 2 diabetes mellitus [13]. The different effects of individual SFA on cardiovascular risk in humans are a well-known phenomenon [14], and it seems that SFA has variable associations with insulin sensitivity, too. These findings show us that the relationship of individual fatty acids to insulin resistance is apparently more complex. For the reasons stated, the specific metabolic effects of individual FAs in insulin resistance pathogenesis became a subject of intensive research. For example, when investigating the effects of palmitoleic acid (16:1n-7, POA), it was demonstrated that POA synthetized in adipose tissue favorably influences lipid and glucose homeostasis in other tissues, such as liver or muscle, and attenuates liver steatosis induced by high-fat diet or diabetes [15, 16]. Nevertheless, the findings on the effects of circulating palmitoleate on cardiometabolic health in humans are still controversial, as the content of POA in plasma lipid classes was an independent marker of abdominal obesity in men [17] or high plasma glucose concentration [18]. Moreover, POA content in erythrocyte membranes has been shown to be associated with inflammation and a higher risk of metabolic syndrome [19].

These discrepant results can be assigned to many factors, including metabolic conversion of POA. The elongation of POA produces cis-vaccenic acid (18:1n-7, cVA), and interestingly, POA, increases the transcription of the genes encoding elongase enzymes, especially ELOVL5 [20], in endothelial cells in a dose-dependent manner [21]. The results of some studies have shown beneficial effects on human health associated with cVA. Erythrocyte membrane cVA was inversely related to the risk of heart failure with antecedent CHD [22], and in one prospective study, lower cVA in PL predicted consistently lower insulin sensitivity and β-cell function over 6 years [23]. In a large prospective cohort study in the US, comprising 3004 participants free of diabetes (men and women) aged >65 years, it was proved that circulating plasma phospholipid cVA was inversely associated with the risk of diabetes mellitus development [24]. These findings indicate that the potential beneficial effects of cVA on cardiometabolic risk in humans should be further studied, also taking into account sex and depot differences between men and women [25]. Hormonal differences are responsible for different metabolism of MUFA and PUFA due to upregulation of desaturases and elongases resulting in higher PUFA n-3 and different deposition and mobilization of fatty acids from visceral and gluteofemoral adipose tissues [26, 27]. The aim of this study was to investigate relations of proportion of cVA in plasma phospholipids to markers of insulin resistance in non-diabetic men with high cardiovascular risk.

Material and methods

Study design and participants

The study population comprised 231 men consecutively examined as outpatients at the 4th Department of Internal Medicine between the years 2020–2022. As a control group, we examined 50 apparently healthy men (volunteers and university staff). The study protocol was approved by the Joint Ethical Committee of the General University Hospital and the first Medical Faculty at Charles University, Prague. Written informed consent was obtained from all participants prior to inclusion. The study was performed in accordance with the Declaration of Helsinki.

These patients were referred to Lipid Clinic to consider the use of hypolipidemic treatment. Subjects studied had an LDL-C level >3.0 mmol/L (7% of probands) and/or triacylglycerolemia >1.70 mmol/L (68.5% of probands). Moreover, we observed low concentrations of high-density lipoprotein cholesterol (HDL-C) (<1.00 mmol/L) in 24% of them. The following exclusion criteria were applied to the study: ongoing lipid-lowering, antidiabetic or antioxidant medication, excessive alcohol consumption (>30 g/day), hormonal replacement therapy, supplementation with polyunsaturated FA (PUFA n-3 and n-6 families), manifestation of cardiovascular disease and/or cerebrovascular disease, diabetes mellitus, liver disease (except for nonalcoholic fatty liver disease), kidney disease (creatinine >130 μmol/L), hypothyroidism, and recent infections and malignancies. Six weeks before the investigation, they were recommended to adhere to the AHA Step One diet and to maintain stable dietary patterns.

Anthropometric and blood pressure measurements

Basic clinical and anthropometric data, including the assessment of body fat, were analyzed using standard methods as described previously [28]. Moreover, the bioelectrical impedance method was used for the body fat mass measurements with Tanita SC-240 (Tanita Corporation, Tokyo, Japan). Blood pressure measurements were performed according to standardized procedures after resting for 10 min, using automated blood pressure devices (Omron M3 Comfort, OMRON Healthcare Europe) by trained study personnel, and the average of two measurements was presented as a result.

Laboratory measurements

Plasma concentrations of biochemical parameters were measured using routine methods, whereas concentrations of nonesterified FA (NEFA) were determined using an enzymatic colorimetric method (Randox Laboratories, UK). The homeostasis model assessment method (HOMA-IR) was used as the index of insulin resistance [29]. The glomerular filtration rate (eGFR) was estimated from serum creatinine according to the 2021 CKD-EPI equation. Fatty acids were analyzed in plasma phospholipids as methyl esters by GC-FID [30] using LN-FAME-HT (60 m × 0.25 mm ID, 0.20 μm df) column (Chromservis s.r.o., Prague, Czech Republic). This setting allowed proper separation of isomers of monounsaturated FA (see Supplementary Fig. 1 for sample chromatogram). The retention times for FA methyl esters were verified using commercially available standards (NuChek Prep Inc., Elysian, MN, USA, Cat. No. GLC-566C and GLC-674). The FID detector performance was checked on the basis of the linearity of the response; the correction factors were calculated using the abovementioned standard mixtures with defined composition. Method variability, presented as a relative standard deviation, ranged from 1.07% for PA (16:0) to 8.60% for 16:1n-9 [31]. Desaturase and elongase activities were estimated using FA product/precursor ratios [32].

Dietary habits

Average intake of energy, proteins, fats, saturated FA, carbohydrates, and fiber were analyzed by a 3-day dietary questionnaire. The nutritional data were analyzed by Nutrimaster SE software, version 1.0 [33].

Statistical methods

The overall group of men was for further comparisons stratified into quartiles according to the content of cis-vaccenic acid in plasma phospholipids; the investigators were blinded according to the quartile assignment. The statistical analysis was performed using the R statistical software Version 4.1.3 [34], or with the STATISTICA® CZ software for Windows (ver. 12). Studies on insulin resistance in subjects with high or low cVA concentrations have not been published to allow sample size calculations; nevertheless, the a posteriori sample size calculations gave power 1-beta 0.76 (HOMA-IR) and 0.66 (insulin) for the current setting.

Categorical data were summarized using absolute and relative frequencies. Continuous data were expressed as the median and interquartile range (IQR, 25th–75th percentile). The normality of the distribution was tested using the Shapiro–Wilks W test. Comparisons between the groups were determined using the independent t-test and the Wilcoxon test, respectively. P-values for both continuous and categorical data were adjusted for multiple comparisons using the Benjamini–Hochberg correction. Multivariate linear regression with backward stepwise analysis was used to distinguish the significance of intercorrelated relevant predictors.

Results

Clinical and biochemical characteristics of the studied group

Basic demographic, anthropometric, and metabolic data of the group of 231 men with hyperlipidemia are shown in Table 1. The median age was 50 years, and the patients were mostly overweight/obese.Table 1 Demographic, anthropometric, metabolic data in men with hyperlipidemia.

	Studied group (n = 231)	
Age (years)	50 [42–60]	
Hypertension [n (%)]	142/231 (61.5%)	
Smokers [n (%)]	78/231 (33.8%)	
BMI (kg m−2)	28.5 [26.01–30.89]	
Waist (cm)	101 [95–108]	
WHCR (ratio)	0.99 [0.95–1.03]	
Fat mass (kg)	25.55 [20.1–32.25]	
Systolic blood pressure (mmHg)	130 [125–140]	
Diastolic blood pressure (mmHg)	85 [80–90]	
LDL-C ≥ 3.0 mmol/L [n (%)]	169/231 (73.1%)	
Waist ≥ 94 cm [n (%)]	183/ 231(79.2%)	
Hypertension [n (%)]	144/231 (62.1%)	
TAG ≥ 1.7 mmol/L [n (%)]	161/231 (68.5%)	
HDL-C ≤ 1.03 mmol/L [n (%)]	66/231 (28.2%)	
f-Glucose ≥ 5.6 mmol/L [n (%)]	70/231 (30.3%)	
Total plasma cholesterol (mmol/L)	5.89 [5.18–6.83]	
Triacylglycerols (mmol/L)	2.16 [1.60–3.36]	
HDL-cholesterol (mmol/L)	1.20 [1.01–1.44]	
LDL-cholesterol (mmol/L)	3.38 [2.94–4.03]	
Non-HDL-cholesterol (mmol/L)	4.66 [3.96–5.62]	
Apolipoprotein B (g/L)	1.23 [1.05–1.50]	
Apolipoprotein A-I (g/L)	1.33 [1.18–1.48]	
f-Glucose (mmol/L)	5.1 [4.7–5.7]	
Insulin (mU/L)	9.27 [6.69–13.61]	
HOMA-IR (index)	2.07 [1.57–3.2]	
NEFA (mmol/L)	0.52 [0.35–0.72]	
Uric acid (μmol/L)	364 [319–418]	
CD-LDL	60.5 [47–73]	
hs-CRP	2.5 [1.17–4.7]	
eGFR (mL/min)	95.7 [82.1–103.1]	
Data are given in median [25th–75th percentile] format, BMI—body mass index [height(m)/weight (kg)2], eGFR—estimated glomerular filtration rate (mL/min/1.73 m2), HOMA index = insulin(mU/L)*glucose(mmol/L)/22.5.

HDL high-density lipoprotein, LDL low-density lipoprotein, TAG triacylglycerols.

Table 2 shows demographic, anthropometric, and metabolic data according to cis-vaccenic acid concentrations in plasma phospholipids. Quartile 4 was compared with Quartile 1 (Q1 and Q4 groups, median [25th–75th percentiles]). Between the groups Q4 and Q1, there were no differences between the daily energy intake and the content of proteins, fats, and carbohydrates, as well. Similarly, we did not observe significant differences in the intakes of dietary FA—saturated FA, monounsaturated FA. and PUFA (as the sum of both PUFA n-3 and n-6) (data not presented).Table 2 Demographic, anthropometric, and metabolic data according to cis-vaccenic acid content in plasma phospholipids (Q1 and Q4 groups).

	Group	
	1st Quartile (n = 57) cVA: [0.57–1.33] mol%	4th Quartile (n = 57) cVA: [1.70–3.30] mol%	
Age (years)	50 [41.5–58]	51 [41.5-57]	
Hypertension [n (%)]	39/57 (68.4%)	34/57 (59.6%)	
Smokers [n (%)]	18/57 (31.6%)	21/57 (36.8%)	
Obesity (BMI > 30 kg m−2) [n (%)]	42/57(73.7%)	48/57 (76.2%)	
BMI (kg m−2)	29.05 [26.55–31.10]	28.60 [25.76–30.85]	
Waist (cm)	102 [94–107]	102 [96–110]	
WHCR (ratio)	0.98 [0.95–1.00]	1.00 [0.95–1.04]	
Fat mass (kg)	25.8 [20.38–33.19]	23.94 [19.08–31.90]	
Systolic blood pressure (mmHg)	135 [130–140]	130 [120-145]	
Diastolic blood pressure (mmHg)	85 [80–90]	80 [80–90]	
LDL-C ≥ 3.0 mmol/L [n (%)]	40/57 (69.8%)	39/57 (68.4%)	
Waist ≥ 94 cm [n (%)]	46/57 (81.2%)	47/57 (82.5%)	
TAG ≥ 1.7 mmol/L [n (%)]	47/57 (82.4%)	39/57 (68.4%)	
HDL-C ≤ 1.03 mmol/L [n (%)]	18/57 (31.6%)	23/57 (40.3%)	
f-Glucose ≥ 5.6 mmol/L [n (%)]	22/57 (38.6%)	16/57 (28.1%)	
Total plasma cholesterol (mmol/L)	5.74 [5.16–7.03]	6.20 [5.27–6.88]	
Triacylglycerols (mmol/L)	2.48 [1.88–3.79]	2.20 [1.62–3.30]	
HDL-cholesterol (mmol/L)	1.12 [1.00–1.32]	1.10 [0.95–1.38]	
LDL-cholesterol (mmol/L)	3.27 [2.84–4.02]	3.54 [2.80–4.26]	
Non-HDL-cholesterol (mmol/L)	4.65 [4.10–5.70]	4.92 [4.12–5.83]	
Apolipoprotein B (g/L)	1.29 [1.08–1.55]	1.12 [0.90–1.42]**a	
Apolipoprotein A-I (g/L)	1.26 [1.17–1.43]	1.32 [1.15–1.52]	
f-Glucose (mmol/L)	5.3 [4.7–5.9]	5.0 [4.6–5.7]	
Insulin (mU/L)	10.90 [7.70–17.19]	8.79 [5.83–11.78]*	
HOMA-IR (index)	2.82 [1.84–4.36]	2.09 [1.42–2.76]*	
NEFA (mmol/L)	0.42 [0.35–0.56]	0.72 [0.57–1.26]**	
Uric acid (μmol/L)	394 [345–435]	371 [308–411]	
CD-LDL (μmol/L)	62.1 [51.0–72.7]	57.4[43.8–67.5]*	
hs-CRP (mg/L)	2.20 [1.10–4.11]	2.00[1.00–3.75]	
eGFR (mL/min)	99.2 [83.9–108.3]	93.5 [81.1–102.8]	
Data are given in median [25th–75th percentile] format. BMI—body mass index [height (m)/weight (kg)2], CD-LDL—conjugated dienes in LDL particles, eGFR—estimated glomerular filtration rate, HDL—high-density lipoprotein, LDL—low-density lipoprotein, MetS—metabolic syndrome, TAG—triacylglycerols; HOMA index = insulin(mU/L)*glucose(mmol/L)/22.5.

at-test with Benjamini–Hochberg correction for multiple comparison: *p < 0.05, **p < 0.01.

In comparison with the Q1 group, the Q4 group was characterized by significantly lower values of insulin, apolipoprotein, and HOMA-IR index, while by significantly higher concentrations of plasma NEFA. Persons in the Q4 group had significantly lower concentrations of conjugated dienes in LDL particles (CD-LDL). Differences in all other variables were not significant (age, BMI, waist circumference, waist-to-hip ratio, fat mass, systolic and diastolic blood pressure), percentage of smokers, as well. There were no significant differences in concentrations of total plasma cholesterol, triacylglycerols, HDL-cholesterol, LDL-cholesterol, non-HDL-cholesterol, apolipoprotein A1, fasting glycemia, uricemia, or hs-CRP. When comparing the control and patient groups, no significant differences were found in age, BMI, proportion of hypertensives, smokers, systolic, and diastolic BP. As expected, significant differences were found in plasma lipid levels (patients with hyperlipidemia differed in significantly higher levels of plasma total cholesterol, triacylglycerols, LDL-C, non-HDL-C, apo B), uric acid, glucose, waist circumference, and index values WHCR. Moreover, controls had a higher proportion of cVA and the sum of MUFA (see Supplementary Tables 3 and 4).

Fatty acid profiles

Fatty acid profiles (mol %) in plasma PL of the Q4 and Q1 groups are shown in Table 3. Q4 group (high cis-vaccenic group) had a higher molar percentage of the sum of MUFA caused by a high content of oleic acid, 18:1n-9, palmitoleic acid, cis-vaccenic and minor FA of this family (cis-hexadecenoic and gondoic acids). The lower content of PUFAn-6 in the Q4 group was more pronounced in minor FA (γ-linolenic and dihomo-γ-linolenic acids); we did not observe significant differences in the content of linoleic and arachidonic acids. The remaining differences in FA concentrations were insignificant after the Benjamini–Hochberg correction.Table 3 Plasma phospholipid FA in Q1 and Q4 groups.

	Group	
	1st Quartile (n = 57) cVA: [0.57–1.33] mol%	4th Quartile (n = 57) cVA: [1.70–3.30] mol%	
14:0a	0.26 [0.23–0.33]	0.22 [0.2–0.34]	
16:0	30.35 [28.80–31.26]	29.41 [27.88–31.01]	
16:1n-9c	0.09 [0.08–0.11]	0.13 [0.11–0.15]***b	
16:1n-7c	0.56 [0.44–0.68]	0.62 [0.51–0.89]*	
18:0	14.26 [13.68–14.9]	14.4 [13.85–15.61]	
18:1n-9c	9.22 [8.52–10.35]	11.53 [10.05–12.67]***	
18:1n-7c	1.23 [1.14–1.29]	1.97 [1.81–2.26]***	
18:2n-6cc	21.49 [19.55–24.28]	21.16 [18.77–22.8]	
18:3n-6alc	0.11 [0.08–0.13]	0.07 [0.06–0.09]***	
18:3n-3alc	0.16 [0.14–0.22]	0.23 [0.18–0.29]***	
20:1n-9c	0.11 [0.10–0.13]	0.17 [0.13–0.22]***	
20:2n-6cc	0.41 [0.34–0.63]	0.41 [0.33–0.58]	
20:3n-6alc	3.33 [2.96–4.14]	3.04 [2.55–3.58]*	
20:4n-6alc	10.77 [9.06–12.21]	10.19 [8.88–11.85]	
20:5n-3alc	0.98 [0.73–1.31]	0.85 [0.66–1.13]	
22:4n-6alc	0.30 [0.23–0.36]	0.32 [0.27–0.39]	
22:5n-6alc	0.18 [0.15–0.25]	0.17 [0.14–0.22]	
22:5n-3alc	0.86 [0.77–1.04]	0.94 [0.78–1.11]	
22:6n-3alc	3.21 [2.60–4.06]	3.09 [2.37–3.98]	
ΣSFA	44.92 [43.62–45.55]	44.22 [43.15–45.82]	
ΣMUFA	11.19 [10.53–12.53]	14.34 [12.85–16.02]***	
ΣPUFAn-6	38.52 [35.72–39.97]	35.23 [33.16–37.43]***	
ΣPUFAn-3	5.44 [4.15–6.79]	5.32 [4.21–5.96]	
Data (mol%) are given in median [25th–75th percentile] format.

alc all cis, c cis, FA fatty acids, ∑ sum, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFAn-6 – polyunsaturated fatty acids of the n-6 family, PUFAn-3 polyunsaturated fatty acids of the n-3 family.

aShorthand notation for FA: carbon number: double bond number, n—position of carbon with first double bond from methyl end.

bt-test with Benjamini–Hochberg correction for multiple comparisons: *p < 0.05, ***p < 0.001.

Surrogate markers of estimated activities of FA desaturases and elongases, computed as the (product/substrate) ratio of respective FA in plasma PL of both Q4 and Q1 groups, are shown in Table 4. In the Q4 group we found raised estimated activity of delta-9-desaturase (D9D) for stearic acid (D9D18) and for palmitic acid (D9D16). Furthermore, we found increased estimated activities for ELOVL5 (calculated as 18:1n-7/16:1n-7 ratio), and ELOVL 2/5 (ratio 22:5n-3/20:5n-3) and 22:4n-6/20:4n-6, respectively. Concurrently, the estimated activity of D6D (ratio 18:3n-6/18:2n-6) was decreased in the Q4 group.Table 4 Estimated activities of the desaturases and elongases in Q1 and Q4 groups.

	Group	
	1st Quartile (n = 57) cVA: [0.57–1.33] mol%	4th Quartile (n = 57) cVA: [1.70–3.30] mol%	
D9D16 (16:1n-7/16:0)	1.82 [1.54–2.19]	2.06 [1.74–2.78]*a	
D9D18 (18:1n-9/18:0)	0.66 [0.60–0.75]	0.76 [0.67–0.85]***	
D5D (20:4n-6/20:3n-6)	3.04 [2.68–3.67]	3.31 [2.84–4.04]	
D6D (18:3n-6/18:2n-6)	0.50 [0.39–0.59]	0.33 [0.25–0.46]**	
ELOVL2/5 (22:5n-3/20:5n-3)	0.88 [0.73–1.04]	1.04 [0.81–1.26]**	
ELOVL2/5 (22:4n-6/20:4n-6)	2.76 [2.39–3.11]	2.97 [2.51–3.79]*	
ELOVL5 (18:1n-7/16:1n-7)	2.15 [1.60–2.72]	3.13 [2.62–4.08]***	
Data are given in median [25th–75th percentile] format.

DnD desaturase, ELOVL elongase for fatty acids; see Table 3 for further abbreviations.

at-test with Benjamini–Hochberg correction for multiple comparisons: *p < 0.05, **p < 0.01, ***p < 0.001.

Correlations between fatty acid profiles and selected variables

Relevant correlations (Spearman´s coefficients, p values) of investigated variables of the total group of 231 men with dyslipidemia are presented in Supplementary Table 1. Cis-vaccenic acid negatively correlated with insulin (r = −0.183, p < 0.01), HOMA-IR (r = −0.196, p < 0.01), apo-B (r = −0.203, p < 0.01). We observed significant correlations with insulin and HOMA-IR for several FA (Supplementary Table 1).

Because of high intercorrelations between all monounsaturated fatty acids (see Supplementary Table 1), we performed backward stepwise regression analysis for all analyzed MUFA to identify significant determination of parameters of insulin resistance with these MUFA. According to backward stepwise analysis, only association with 18:1n-7c remains significant for insulin (p = 0.015) and HOMA-IR (p = 0.006) (see Supplementary Table 2 for detailed results).

Discussion

In this study, we have found significant differences in the parameters of glucose and lipid homeostasis between the patients belonging to the upper (group Q4) vs. lower (Q1) quartile of the cis-vaccenic acid content in plasma phospholipids (PL). Fatty acid profiles of the Q4 and Q1 groups significantly differed, as well. To our knowledge, it is the first study investigating associations of high vs. low proportions of cis-vaccenic acid in plasma phospholipids (PL) with markers of insulin resistance in men with hyperlipidemia.

The main finding of the study was that individuals in group Q4 differed from those in Q1 by the more favorable profile of insulin resistance markers. They had significantly lower plasma insulin, HOMA-IR values, and apolipoprotein B concentrations. Moreover, both quartiles differed significantly in the composition of FA in plasma PL. The individuals in the Q4 group had lower proportions of FA 14:0, 18:3n-6, 20:3n-6, and the sum of PUFA n-6. On the other hand, the Q4 group had, besides cVA, significantly elevated FA 16:1n-9, 16:1n-7, 18:1n-9, 20:1n-9, 18:3n-3, sum of MUFA and total plasma NEFA.

We did not prove different dietary habits between Q1 and Q4 subjects (data not shown). It is known that dietary assessment methods have many limitations. The accuracy for individual dietary components reaches a maximum of 70–80% [35].

While insulin and HOMA-IR values serve as surrogate markers of insulin resistance, elevated apolipoprotein B, concurrently with elevated serum triacylglycerols, increased small LDL particles, and reduced level of HDL characterize atherogenic dyslipidemia that is typical for insulin resistant states. Interestingly, the whole group of 231 men with hyperlipidemia had a significantly smaller proportion of cVA and oleic acid in their plasma PL, in comparison with a small control group of 50 normolipidemic men (see Supplementary Tables S2, S3).

Our findings of associations of plasma phospholipid cis-vaccenic acid (18:1n-7) with cardiometabolic risk factors are in line with the results of several studies. In participants of a prospective Cardiovascular Health Study, free of diabetes, concentrations of 18:1n-7 in plasma PL were inversely associated with incident T2DM [24]. From another perspective, in a 6-year study in the Canadian population at risk for diabetes, lower cis-vaccenic acid (cVA) predicted lower insulin sensitivity and β-cell function [23]. Ethnic factors may also play a role in the functioning of cVA. In Multi-Ethnic Study of Atherosclerosis (MESA) participants, higher levels of plasma cVA were inversely associated with insulin resistance scores across four races/ethnicities (Caucasian, Black, American Chinese, Hispanic), and related to 17%, 39%, and 32% lower risks of incident T2DM in Black, Chinese American, and Hispanic participants, respectively. In Caucasians, the significant association of cVA with incident T2DM was not found [36]. In other studies, different results were found, too. In the European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam study, cVA by quintile of erythrocyte membrane fatty acid proportions did not correlate with the risk of T2DM [37].

The Q4 group differed from the Q1 group by a higher level of individual MUFAs (16:1n-9, 18:1n-9, 20:1n-9) and palmitoleic acid (16:1n-7, POA), which is a precursor of cVA. The levels of α-linolenic acid (18:3n-3, LnA) and total plasma NEFA were higher in the Q4 group, as well.

MUFA, mostly oleic acid, is recognized as beneficial in influencing insulin sensitivity and preventing DM2. However, not all FA in this class have the same effects. Oleic acid (OA) content has been linked with a number of mechanisms, such as reduced expression of pro-inflammatory genes, upregulation of enzymes responsible for fatty acid oxidation, beneficial effects on endothelial dysfunction, and others [38]. Negative correlations with T2DM were found for OA in both plasma CE [39] and plasma PL [13]. On the other hand, some studies also produced opposite results - in one prospective study, oleic and palmitoleic (POA) acids were independently associated with incident T2DM [40].

Q1 differed from Q4 by significantly higher concentrations of γ-linolenic acid (GLA) and dihomo-γ-linolenic acid (DGLA) while lower proportions of sum PUFA n-6 (at the expense of linoleic acid, LA) and α-linolenic acid (ALA, 18:3n-3). In our previous work, higher proportions of POA, GLA, and DGLA, while lower content of LA in plasma phosphatidylcholines were able to identify in the patients with metabolic syndrome those with higher IR or an oxidative stress marker [33]. Also, DGLA was associated with abdominal fat expressed as waist circumference or waist/hip ratio [41].

In this work, we observed higher levels of NEFA in the Q4 vs. Q1 group. It was generally accepted that elevated plasma NEFA is associated with insulin resistance and T2DM in humans [42]. NEFA was elevated in diabetic subjects with overweight/obesity in comparison with healthy subjects [43] and was prospectively associated with an increased risk of both impaired glucose tolerance and T2DM [44]. Nevertheless, individual NEFA may have different effects on the progress of insulin resistance and the development of type 2 diabetes mellitus [45]. Saturated NEFA causes insulin resistance, while monounsaturated FA increases insulin sensitivity in both diabetic [46] and healthy persons [45].

Still, some issues are to be resolved dealing with different NEFA contribution to insulin resistance and other pathologic states: FA profiles in plasma lipid compartments differ significantly between men and women and among different ethnic groups, as well [47], and reference range for main plasma FA in healthy subjects are missing [48].

The reasons for the higher NEFA concentration in the Q4 group are not clear. Some findings suggest that increased content of cis vaccenic acid, a product of ELOVL5 activity, could be related to a decrease in ectopic fat deposition. Supplementation of obese rats with trans-vaccenic acid (replacing oleic acid) led to increased insulin sensitivity, reduced hepatic steatosis, and decreased nonalcoholic fatty liver disease activity scores. The action of cVA on PPARγ (peroxisome proliferator activator receptor γ) in adipose tissue may counteract excessive ectopic lipid accumulation [49]. In our study, in set of men with hyperlipidemia group of patients belonging to the fourth quartile of serum PL cVA proportions had higher values of estimated ELOVL2/5 activity, calculated both as a 22:5n-3/20:5 n-3 and 22:4n-6/20:4n-6 ratios and activity of ELOVL5 calculated as a ratio 18:1n-7/16:1n-7. In experimental work, increasing hepatic ELOVL5 activity improved glycemia, insulinemia, HOMA-IR, and glucose tolerance to normal values in obese mice [50]. In mice with a knockout of the Elovl5 gene, the lack of endogenously formed long-chain PUFA leads to the derepression of SREBP-1c, the activation of lipogenesis, and hepatic steatosis [51]. ELOVL5 activity was also associated with increased catabolism of triacylglycerols, suppressed expression of enzymes involved in gluconeogenesis [52], and induced the expression of fibroblast growth factor 21 (FGF21), which increases hepatic insulin sensitivity, decreases lipogenesis, potentiates fatty acid β-oxidation, reduces hepatic ER (endoplasmic reticulum) stress, and diminishes VLDL (very low-density lipoproteins) delivery to the liver [53] and can improve ectopic lipid deposition in liver and muscle [54].

The patients in the Q4 group had significantly higher estimated activities of delta-9-desaturase (D9D) both for 16:0 (D9D16) and 18:0 (D9D18), whereas lower estimated activity of D6D (calculated as 18:3n-6/18:2n-6 ratio). Elevated activity of D9D is a marker of de novo lipogenesis, and in this study, both D9D16 and D9D18 correlated significantly with the total plasma NEFA levels and with all principal n-9 FA (16:1n-7, 18:1n-9, 20:1n-9, and cVA.

Interestingly, the estimated activity (D9D18) index correlated negatively with markers of insulin resistance, whereas the D9D16 index correlated positively (see Supplementary Table 1). This probably could be related to the possible positive association of POA with insulin resistance in this set of patients.

Proportion of cVA correlated negatively with insulin, HOMA-IR, and apolipoprotein B, showing that in our set of hyperlipidemic patients with obesity/overweight, cVA in plasma PL may function to improve insulin sensitivity. In contrast, POA correlated rather differently both with anthropometric parameters and markers of glucose and lipid homeostasis. Its proportion in plasma PL correlated positively with BMI, WHCR, fat mass, and triacylglycerols. This finding corresponds with some results of previous human studies, indicating unfavorable effects of POA on glucose homeostasis [19], though not all studies did prove such results [24].

Patients of Q4, in comparison with the Q1 group, had significantly lower values of an estimated D6D (18:3n6/18:2n6) (p < 0.001). This finding is in line with the results of other studies, where elevated estimated activity of D6D was described in patients with metabolic syndrome and T2DM [31], impaired fasting glycemia [30], and other pathologic conditions such as cardiovascular disease [55], tumors [9], or depression [10] Inverse correlations have been found between POA and cVA with estimated D6D activity (while POA correlated positively, cVA correlated negatively, both p < 0.001).

We have analyzed in our group of hyperlipidemic men markers of oxidative stress and inflammation (conjugated dienes in LDL and hs-CRP), as these conditions are associated with insulin resistance. Probands in the Q4 group had significantly lower concentrations of CD-LDL in comparison with the Q1 group. Concentrations of CD-LDL are considered a marker of systemic oxidative stress, partly reflecting the levels of minimally modified LDL, in which only the lipid component is oxidatively modified [56]. This finding is in line with the results of our earlier studies dealing with hypertriglyceridemia, severity of metabolic syndrome, or pancreatic cancer, as well [9, 26, 57]. The significance of lipid peroxidation in the pathogenesis of insulin resistance has been proven in experimental and clinical studies [58].

On the other hand, we were not able to find differences in hs-CRP concentrations. To our knowledge, this is the first work describing significant associations of serum PL cVA with parameters of insulin sensitivity in male patients with hyperlipidemia.

The study was conducted in a relatively large set of men with overweight or obesity, who were not treated with lipid-lowering drugs, supplements of n-3 or n-6 PUFA, or antioxidants. Limitations include a cross-sectional type of study, so causality could not be proved. Moreover, the profile of individual plasma NEFA was not investigated, and the content of individual MUFA and PUFA was not assessed in dietary questionnaires, as well. Also, the data about the physical activity were not available.

Our results support the hypothesis that plasma PL cis-vaccenic acid could be associated with insulin sensitivity in men with hyperlipidemia and high cardiovascular risk. Moreover, the results indicate that individual FA in the same class can have different pathophysiological effects. The results should be further studied and applied to other populations, e.g. healthy subjects, women, or type 2 diabetics.

Supplementary information

Supplementary Tables 1-5 and supplementary Figure 1

Supplementary information

The online version contains supplementary material available at 10.1038/s41387-024-00332-z.

Acknowledgements

This research was funded by the Ministry of Health of the Czech Republic, grants number MH CZ DRO-VFN64165 and NU23-01-00288, and the Ministry of Education, Youth and Sports of the Czech Republic, grant the Charles University Research program, Cooperatio—Gastroenterology, The statistical help of Barbora Pejchalová is greatly acknowledged.

Author contributions

Conceptualization, JM, MZ, RB, and MV; methodology, MV and BS; writing—original draft preparation, MZ, JM, MV, and AZ; writing—review and editing, MV, M.Z, and JM; super-vision, MZ, RB, and JM; project administration, MV, MR, and SK; funding acquisition, AZ and RB. All authors have read and agreed to the published version of the manuscript.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. de Carvalho CCCR Caramujo MJ The various roles of fatty acids Molecules 2018 23 2583 10.3390/molecules23102583 30304860
de Carvalho CCCR, Caramujo MJ. The various roles of fatty acids. Molecules. 2018;23:2583.30304860 10.3390/molecules23102583
2. Guillou H Zadravec D Martin PG Jacobsson A The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice Prog Lipid Res 2010 49 186 99 10.1016/j.plipres.2009.12.002 20018209
Guillou H, Zadravec D, Martin PG, Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice. Prog Lipid Res. 2010;49:186–99.20018209 10.1016/j.plipres.2009.12.002
3. Zeman M Vecka M Jáchymová M Jirák R Tvrzická E Staňková B Fatty acid CoA ligase-4 gene polymorphism influences fatty acid metabolism in metabolic syndrome, but not in depression Tohoku J Exp Med 2009 217 287 93 10.1620/tjem.217.287 19346733
Zeman M, Vecka M, Jáchymová M, Jirák R, Tvrzická E, Staňková B, et al. Fatty acid CoA ligase-4 gene polymorphism influences fatty acid metabolism in metabolic syndrome, but not in depression. Tohoku J Exp Med. 2009;217:287–93.19346733 10.1620/tjem.217.287
4. Smith CE Ordovás JM Fatty acid interactions with genetic polymorphisms for cardiovascular disease Curr Opin Clin Nutr Metab Care 2010 13 139 44 10.1097/MCO.0b013e3283357287 19996744
Smith CE, Ordovás JM. Fatty acid interactions with genetic polymorphisms for cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2010;13:139–44.19996744 10.1097/MCO.0b013e3283357287
5. Yaribeygi H Farrokhi FR Butler AE Sahebkar A Insulin resistance: Review of the underlying molecular mechanisms J Cell Physiol 2019 234 8152 61 10.1002/jcp.27603 30317615
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. J Cell Physiol. 2019;234:8152–61.30317615 10.1002/jcp.27603
6. Warensjö E Risérus U Vessby B Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men Diabetologia 2005 48 1999 2005 10.1007/s00125-005-1897-x 16132958
Warensjö E, Risérus U, Vessby B. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia. 2005;48:1999–2005.16132958 10.1007/s00125-005-1897-x
7. Roden M Shulman GI The integrative biology of type 2 diabetes Nature 2019 576 51 60 10.1038/s41586-019-1797-8 31802013
Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51–60.31802013 10.1038/s41586-019-1797-8
8. Jornayvaz FR Samuel VT Shulman GI The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome Annu Rev Nutr 2010 30 273 90 10.1146/annurev.nutr.012809.104726 20645852
Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr. 2010;30:273–90.20645852 10.1146/annurev.nutr.012809.104726
9. Macášek J Vecka M Žák A Urbánek M Krechler T Petruželka L Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parameters Nutr Cancer 2012 64 946 55 10.1080/01635581.2012.716138 23061902
Macášek J, Vecka M, Žák A, Urbánek M, Krechler T, Petruželka L, et al. Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parameters. Nutr Cancer. 2012;64:946–55.23061902 10.1080/01635581.2012.716138
10. Vařeka T Vecka M Jirák R Tvrzická E Macášek J Žák A Plasma fatty acid profile in depressive disorder resembles insulin resistance state Neuro Endocrinol Lett 2012 33 83 86 23183516
Vařeka T, Vecka M, Jirák R, Tvrzická E, Macášek J, Žák A, et al. Plasma fatty acid profile in depressive disorder resembles insulin resistance state. Neuro Endocrinol Lett. 2012;33:83–86.23183516
11. Sears B Perry M The role of fatty acids in insulin resistance Lipids Health Dis 2015 14 121 10.1186/s12944-015-0123-1 26415887
Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121 10.1186/s12944-015-0123-126415887 10.1186/s12944-015-0123-1
12. Wu JHY Marklund M Imamura F Tintle N Ardisson Korat AV de Goede J Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies Lancet Diabetes Endocrinol 2017 5 965 74 10.1016/S2213-8587(17)30307-8 29032079
Wu JHY, Marklund M, Imamura F, Tintle N, Ardisson Korat AV, de Goede J, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017;5:965–74.29032079 10.1016/S2213-8587(17)30307-8
13. Wang L Folsom AR Zheng ZJ Pankow JS Eckfeldt JH Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study Am J Clin Nutr 2003 78 91 8 10.1093/ajcn/78.1.91 12816776
Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. 2003;78:91–8.12816776 10.1093/ajcn/78.1.91
14. Perna M Hewlings S Saturated fatty acid chain length and risk of cardiovascular disease: a systematic review Nutrients 2022 15 30 10.3390/nu15010030 36615688
Perna M, Hewlings S. Saturated fatty acid chain length and risk of cardiovascular disease: a systematic review. Nutrients. 2022;15:30.36615688 10.3390/nu15010030
15. Cao H Gerhold K Mayers JR Wiest MM Watkins SM Hotamisligil GS Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism Cell 2008 134 933 44 10.1016/j.cell.2008.07.048 18805087
Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008;134:933–44.18805087 10.1016/j.cell.2008.07.048
16. de Souza CO Teixeira AAS Biondo LA Lima Junior EA Batatinha HAP Rosa Neto JC Palmitoleic acid improves metabolic functions in fatty liver by PPARα-dependent AMPK activation J Cell Physiol 2017 232 2168 77 10.1002/jcp.25715 27925195
de Souza CO, Teixeira AAS, Biondo LA, Lima Junior EA, Batatinha HAP, Rosa Neto JC. Palmitoleic acid improves metabolic functions in fatty liver by PPARα-dependent AMPK activation. J Cell Physiol. 2017;232:2168–77.27925195 10.1002/jcp.25715
17. Paillard F Catheline D Duff FL Bouriel M Deugnier Y Pouchard M Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity Nutr Metab Cardiovasc Dis 2008 18 436 40 10.1016/j.numecd.2007.02.017 18068341
Paillard F, Catheline D, Duff FL, Bouriel M, Deugnier Y, Pouchard M, et al. Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. Nutr Metab Cardiovasc Dis. 2008;18:436–40.18068341 10.1016/j.numecd.2007.02.017
18. Lindgärde F Vessby B Ahrén B Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women Am J Clin Nutr 2006 84 1009 13 10.1093/ajcn/84.5.1009 17093151
Lindgärde F, Vessby B, Ahrén B. Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women. Am J Clin Nutr. 2006;84:1009–13.17093151 10.1093/ajcn/84.5.1009
19. Zong G Ye X Sun L Li H Yu Z Hu FB Associations of erythrocyte palmitoleic acid with adipokines, inflammatory markers, and the metabolic syndrome in middle-aged and older Chinese Am J Clin Nutr 2012 96 970 6 10.3945/ajcn.112.040204 23015321
Zong G, Ye X, Sun L, Li H, Yu Z, Hu FB, et al. Associations of erythrocyte palmitoleic acid with adipokines, inflammatory markers, and the metabolic syndrome in middle-aged and older Chinese. Am J Clin Nutr. 2012;96:970–6.23015321 10.3945/ajcn.112.040204
20. Wang Y Botolin D Xu J Christian B Mitchell E Jayaprakasam B Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity J Lipid Res 2006 47 2028 41 10.1194/jlr.M600177-JLR200 16790840
Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res. 2006;47:2028–41.16790840 10.1194/jlr.M600177-JLR200
21. de Souza CO Vannice GK Rosa Neto JC Calder PC Is palmitoleic acid a plausible nonpharmacological strategy to prevent or control chronic metabolic and inflammatory disorders? Mol Nutr Food Res 2018 62 1700504 10.1002/mnfr.201700504
de Souza CO, Vannice GK, Rosa Neto JC, Calder PC. Is palmitoleic acid a plausible nonpharmacological strategy to prevent or control chronic metabolic and inflammatory disorders? Mol Nutr Food Res. 2018;62:1700504.10.1002/mnfr.201700504
22. Djoussé L Matsumoto C Hanson NQ Weir NL Tsai MY Gaziano JM Plasma cis-vaccenic acid and risk of heart failure with antecedent coronary heart disease in male physicians Clin Nutr 2014 33 478 82 10.1016/j.clnu.2013.07.001 23880347
Djoussé L, Matsumoto C, Hanson NQ, Weir NL, Tsai MY, Gaziano JM. Plasma cis-vaccenic acid and risk of heart failure with antecedent coronary heart disease in male physicians. Clin Nutr. 2014;33:478–82.23880347 10.1016/j.clnu.2013.07.001
23. Johnston LW Harris SB Retnakaran R Zinman B Giacca A Liu Z Longitudinal associations of phospholipid and cholesteryl ester fatty acids with disorders underlying diabetes J Clin Endocrinol Metab 2016 101 2536 44 10.1210/jc.2015-4267 27144932
Johnston LW, Harris SB, Retnakaran R, Zinman B, Giacca A, Liu Z, et al. Longitudinal associations of phospholipid and cholesteryl ester fatty acids with disorders underlying diabetes. J Clin Endocrinol Metab. 2016;101:2536–44.27144932 10.1210/jc.2015-4267
24. Ma W Wu JHY Wang Q Lemaitre RN Mukamal KJ Djousse I Prospective association of fatty acids in de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study1–5 Am J Clin Nutr 2015 101 153 63 10.3945/ajcn.114.092601 25527759
Ma W, Wu JHY, Wang Q, Lemaitre RN, Mukamal KJ, Djousse I, et al. Prospective association of fatty acids in de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study1–5. Am J Clin Nutr. 2015;101:153–63.25527759 10.3945/ajcn.114.092601
25. Ramos P Bush NC Jensen MD Sex and depot differences in palmitoleic acid content of human blood and fat Lipids 2020 55 63 72 10.1002/lipd.12212 31944322
Ramos P, Bush NC, Jensen MD. Sex and depot differences in palmitoleic acid content of human blood and fat. Lipids. 2020;55:63–72.31944322 10.1002/lipd.12212
26. Childs CE Romeu-Nadal M Burdge GC Calder PC Gender differences in the n-3 fatty acid content of tissues Proc Nutr Soc 2008 67 19 27 10.1017/S0029665108005983 18234128
Childs CE, Romeu-Nadal M, Burdge GC, Calder PC. Gender differences in the n-3 fatty acid content of tissues. Proc Nutr Soc. 2008;67:19–27.18234128 10.1017/S0029665108005983
27. Varlamov O Bethea CL Roberts CT Jr Sex-specific differences in lipid and glucose metabolism Front Endocrinol (Lausanne) 2015 5 241 10.3389/fendo.2014.00241 25646091
Varlamov O, Bethea CL, Roberts CT Jr. Sex-specific differences in lipid and glucose metabolism. Front Endocrinol (Lausanne). 2015;5:241.25646091 10.3389/fendo.2014.00241
28. Žák A Tvrzická E Vecka M Jáchymová M Duffková L Staňková B Severity of metabolic syndrome unfavorably influences oxidative stress and fatty acid metabolism in men Tohoku J Exp Med 2007 212 359 71 10.1620/tjem.212.359 17660701
Žák A, Tvrzická E, Vecka M, Jáchymová M, Duffková L, Staňková B, et al. Severity of metabolic syndrome unfavorably influences oxidative stress and fatty acid metabolism in men. Tohoku J Exp Med. 2007;212:359–71.17660701 10.1620/tjem.212.359
29. Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1985 28 412 9 10.1007/BF00280883 3899825
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.3899825 10.1007/BF00280883
30. Vecka M Tvrzická E Staňková B Žák A Effect of column and software on gas chromatographic determination of fatty acids J Chromatogr B Anal Technol Biomed Life Sci 2002 770 91 9 10.1016/S1570-0232(01)00630-4
Vecka M, Tvrzická E, Staňková B, Žák A. Effect of column and software on gas chromatographic determination of fatty acids. J Chromatogr B Anal Technol Biomed Life Sci. 2002;770:91–9.10.1016/S1570-0232(01)00630-4
31. Tvrzická E Vecka M Staňková B Žák A Analysis of fatty acids in plasma lipoproteins by gas chromatography-flame ionisation detection. Quantitative aspects Anal Chim Acta 2002 465 337 50 10.1016/S0003-2670(02)00396-3
Tvrzická E, Vecka M, Staňková B, Žák A. Analysis of fatty acids in plasma lipoproteins by gas chromatography-flame ionisation detection. Quantitative aspects. Anal Chim Acta. 2002;465:337–50.10.1016/S0003-2670(02)00396-3
32. Macášek J Zeman M Žák A Staňková B Vecka M Altered indices of fatty acid elongases ELOVL6, ELOVL5, and ELOVL2 activities in patients with impaired fasting glycemia Metab Syndr Relat Disord 2021 19 386 92 10.1089/met.2021.0012 33983851
Macášek J, Zeman M, Žák A, Staňková B, Vecka M. Altered indices of fatty acid elongases ELOVL6, ELOVL5, and ELOVL2 activities in patients with impaired fasting glycemia. Metab Syndr Relat Disord. 2021;19:386–92.33983851 10.1089/met.2021.0012
33. Žák A Burda M Vecka M Zeman M Tvrzická E Staňková B Fatty acid composition indicates two types of metabolic syndrome independent of clinical and laboratory parameters Physiol Res 2014 63 S375 85 10.33549/physiolres.932868 25428743
Žák A, Burda M, Vecka M, Zeman M, Tvrzická E, Staňková B. Fatty acid composition indicates two types of metabolic syndrome independent of clinical and laboratory parameters. Physiol Res. 2014;63:S375–85.25428743 10.33549/physiolres.932868
34. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2024
35. Thompson FE, Subar AF. Dietary assessment methodology. In: Coulston AM, Boushey CJ, Ferruzzi MG, editors. Nutrition in the prevention and treatment of disease. USA: Elsevier Inc.; 2013. pp. 5–46.
36. Weir NL Steffen BT Guan W Johnson LM Djousse L Mukamal KJ Circulating omega-7 fatty acids are differentially related to metabolic dysfunction and incident type II diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA) Diabetes Metab 2020 46 319 25 10.1016/j.diabet.2019.10.005 31706030
Weir NL, Steffen BT, Guan W, Johnson LM, Djousse L, Mukamal KJ, et al. Circulating omega-7 fatty acids are differentially related to metabolic dysfunction and incident type II diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Metab. 2020;46:319–25.31706030 10.1016/j.diabet.2019.10.005
37. Kröger J Zietemann V Enzenbach C Weikert C Jansen EH Döring F Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study Am J Clin Nutr 2011 93 127 42 10.3945/ajcn.110.005447 20980488
Kröger J, Zietemann V, Enzenbach C, Weikert C, Jansen EH, Döring F, et al. Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr. 2011;93:127–42.20980488 10.3945/ajcn.110.005447
38. Rehman K Haider K Jabeen K Akash MSH Current perspectives of oleic acid: Regulation of molecular pathways in mitochondrial and endothelial functioning against insulin resistance and diabetes Rev Endocr Metab Disord 2020 21 631 43 10.1007/s11154-020-09549-6 32125563
Rehman K, Haider K, Jabeen K, Akash MSH. Current perspectives of oleic acid: Regulation of molecular pathways in mitochondrial and endothelial functioning against insulin resistance and diabetes. Rev Endocr Metab Disord. 2020;21:631–43.32125563 10.1007/s11154-020-09549-6
39. Vessby B Aro A Skarfors E Berglund L Salminen I Lithell H The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters Diabetes 1994 43 1353 7 10.2337/diab.43.11.1353 7926311
Vessby B, Aro A, Skarfors E, Berglund L, Salminen I, Lithell H. The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes. 1994;43:1353–7.7926311 10.2337/diab.43.11.1353
40. Qureshi W Santaren ID Hanley AJ Watkins SM Lorenzo C Wagenknecht LE Risk of diabetes associated with fatty acids in the de novo lipogenesis pathway is independent of insulin sensitivity and response: the Insulin Resistance Atherosclerosis Study (IRAS) BMJ Open Diabetes Res Care 2019 7 e000691 10.1136/bmjdrc-2019-000691 31543975
Qureshi W, Santaren ID, Hanley AJ, Watkins SM, Lorenzo C, Wagenknecht LE. Risk of diabetes associated with fatty acids in the de novo lipogenesis pathway is independent of insulin sensitivity and response: the Insulin Resistance Atherosclerosis Study (IRAS). BMJ Open Diabetes Res Care. 2019;7:e000691.31543975 10.1136/bmjdrc-2019-000691
41. Zeman M Vecka M Burda M Tvrzická E Staňková B Macášek J Fatty acid composition of plasma phosphatidylcholine determines body fat parameters in subjects with metabolic syndrome-related traits Metab Syndr Relat Disord 2017 15 371 8 10.1089/met.2017.0040 28727953
Zeman M, Vecka M, Burda M, Tvrzická E, Staňková B, Macášek J, et al. Fatty acid composition of plasma phosphatidylcholine determines body fat parameters in subjects with metabolic syndrome-related traits. Metab Syndr Relat Disord. 2017;15:371–8.28727953 10.1089/met.2017.0040
42. Boden G Role of fatty acids in the pathogenesis of insulin resistance and NIDDM Diabetes 1997 46 3 10 10.2337/diab.46.1.3 8971073
Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46:3–10.8971073 10.2337/diab.46.1.3
43. Ni Y Zhao L Yu H Ma X Bao Y Rajani C Circulating unsaturated fatty acids delineate the metabolic status of obese individuals EBioMedicine 2015 2 1513 22 10.1016/j.ebiom.2015.09.004 26629547
Ni Y, Zhao L, Yu H, Ma X, Bao Y, Rajani C, et al. Circulating unsaturated fatty acids delineate the metabolic status of obese individuals. EBioMedicine. 2015;2:1513–22.26629547 10.1016/j.ebiom.2015.09.004
44. Salgin B Ong KK Thankamony A Emmett P Wareham NJ Dunger DB Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes J Clin Endocrinol Metab 2012 97 3302 9 10.1210/jc.2012-1428 22740706
Salgin B, Ong KK, Thankamony A, Emmett P, Wareham NJ, Dunger DB. Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. J Clin Endocrinol Metab. 2012;97:3302–9.22740706 10.1210/jc.2012-1428
45. Vessby B Uusitupa M Hermansen K Riccardi G Rivellese AA Tapsell LC KANWU Study Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study Diabetologia 2001 44 312 9 10.1007/s001250051620 11317662
Vessby B, Uusitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC.KANWU Study et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU study. Diabetologia. 2001;44:312–9.11317662 10.1007/s001250051620
46. Parillo M Rivelles AA Ciardullo AV Capaldo B Giacco A Genovese S A high monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients Metabolism 1992 41 1373 8 10.1016/0026-0495(92)90111-M 1461145
Parillo M, Rivelles AA, Ciardullo AV, Capaldo B, Giacco A, Genovese S, et al. A high monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. Metabolism. 1992;41:1373–8.1461145 10.1016/0026-0495(92)90111-M
47. Abdelmagid SA Clarke SE Nielsen DE Badawi A El-Sohemy A Mutch DM Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults PLoS ONE 2015 10 e0116195 10.1371/journal.pone.0116195 25675440
Abdelmagid SA, Clarke SE, Nielsen DE, Badawi A, El-Sohemy A, Mutch DM, et al. Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PLoS ONE. 2015;10:e0116195.25675440 10.1371/journal.pone.0116195
48. Chandra K Jain V Jain SK Plasma non-esterified fatty acids (NEFA) in type 2 diabetes mellitus: evidence on pathophysiology J Diabetes Clin Res 2021 3 46 50
Chandra K, Jain V, Jain SK. Plasma non-esterified fatty acids (NEFA) in type 2 diabetes mellitus: evidence on pathophysiology. J Diabetes Clin Res. 2021;3:46–50.
49. Jacome-Sosa MM Borthwick F Mangat R Uwiera R Reaney MJ Shen J Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome J Nutr Biochem 2014 25 692 701 10.1016/j.jnutbio.2014.02.011 24775093
Jacome-Sosa MM, Borthwick F, Mangat R, Uwiera R, Reaney MJ, Shen J, et al. Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome. J Nutr Biochem. 2014;25:692–701.24775093 10.1016/j.jnutbio.2014.02.011
50. Tripathy S Torres-Gonzalez M Jump DB Elevated hepatic fatty acid elongase-5 activity corrects dietary fat induced hyperglycemia in obese C57BL/6J mice J Lipid Res 2010 51 2642 54 10.1194/jlr.M006080 20488798
Tripathy S, Torres-Gonzalez M, Jump DB. Elevated hepatic fatty acid elongase-5 activity corrects dietary fat induced hyperglycemia in obese C57BL/6J mice. J Lipid Res. 2010;51:2642–54.20488798 10.1194/jlr.M006080
51. Moon YA Hammer RE Horton JD Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice J Lipid Res 2009 50 412 23 10.1194/jlr.M800383-JLR200 18838740
Moon YA, Hammer RE, Horton JD. Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res. 2009;50:412–23.18838740 10.1194/jlr.M800383-JLR200
52. Jump DB Tripathy S Depner CM Fatty acid-regulated transcription factors in the liver Annu Rev Nutr 2013 33 249 69 10.1146/annurev-nutr-071812-161139 23528177
Jump DB, Tripathy S, Depner CM. Fatty acid-regulated transcription factors in the liver. Annu Rev Nutr. 2013;33:249–69.23528177 10.1146/annurev-nutr-071812-161139
53. Falamarzi K Malekpour M Tafti MF Azarpira N Behboodi M Zarei M The role of FGF21 and its analogs on liver associated diseases Front Med (Lausanne) 2022 9 967375 10.3389/fmed.2022.967375 36457562
Falamarzi K, Malekpour M, Tafti MF, Azarpira N, Behboodi M, Zarei M. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne). 2022;9:967375.36457562 10.3389/fmed.2022.967375
54. Jia Y Yu H Liang J Zhang Q Sun J Yang H Increased FGF-21 improves ectopic lipid deposition in the liver and skeletal muscle Nutrients 2024 16 1254 10.3390/nu16091254 38732501
Jia Y, Yu H, Liang J, Zhang Q, Sun J, Yang H, et al. Increased FGF-21 improves ectopic lipid deposition in the liver and skeletal muscle. Nutrients. 2024;16:1254.38732501 10.3390/nu16091254
55. Warensjö E Sundström J Vessby B Cederholm T Risérus U Markers of dietary fat quality and fatty acid desaturation as redictors of total and cardiovascular mortality: a population-based prospective study Am J Clin Nutr 2008 88 203 9 10.1093/ajcn/88.1.203 18614742
Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat quality and fatty acid desaturation as redictors of total and cardiovascular mortality: a population-based prospective study. Am J Clin Nutr. 2008;88:203–9.18614742 10.1093/ajcn/88.1.203
56. Ahotupa M Ruutu M Mäntylä E Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins Clin Biochem 1996 29 139 44 10.1016/0009-9120(95)02043-8 8601322
Ahotupa M, Ruutu M, Mäntylä E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem. 1996;29:139–44.8601322 10.1016/0009-9120(95)02043-8
57. Zeman M Žák A Vecka M Tvrzická E Romaniv S Konárková M Treatment of hypertriglyceridaemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoperoxidation of LDL Ann N Y Acad Sci 2002 967 336 41 10.1111/j.1749-6632.2002.tb04289.x 12079861
Zeman M, Žák A, Vecka M, Tvrzická E, Romaniv S, Konárková M. Treatment of hypertriglyceridaemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoperoxidation of LDL. Ann N Y Acad Sci. 2002;967:336–41.12079861 10.1111/j.1749-6632.2002.tb04289.x
58. Murdolo G Piroddi M Luchetti F Tortoioli C Canonico B Zerbinati C Oxidative stress and lipid peroxidation by-products at the crossroad between adipose organ dysregulation and obesity-linked insulin resistance Biochimie 2013 95 585 94 10.1016/j.biochi.2012.12.014 23274128
Murdolo G, Piroddi M, Luchetti F, Tortoioli C, Canonico B, Zerbinati C, et al. Oxidative stress and lipid peroxidation by-products at the crossroad between adipose organ dysregulation and obesity-linked insulin resistance. Biochimie. 2013;95:585–94.23274128 10.1016/j.biochi.2012.12.014
